



CD4⁺ T Cells Play a Critical Role in Mediating Hypertension in Response to Placental Ischemia

Sarah Novotny, Kedra Wallace, Florian Herse, Janae Moseley, Marie Darby, Judith Heath, James Gill, Gerd Wallukat, James N Martin, Ralf Dechend and Babbette LaMarca*

Department of Obstetrics & Gynecology, University of Mississippi Medical Center, USA

Abstract

Similar to preeclamptic women, hypertension in the chronic Reduced Uterine Perfusion Pressure Rat Model Of Preeclampsia (RUPP) is associated with increased CD4⁺ T cells, cytokines, sFlt-1 and agonistic autoantibodies to the AngII receptor (AT1-AA). We examined the effect inhibition of T cell co-stimulation in RUPP rats treated with (A) (abatacept, 250 mg/kg, infused i.v. at gestation day 13), on hypertension and sFlt-1, TNF- α and AT1-AA. RUPP surgical procedure was performed on day 14. On day 19 MAP increased from 94 \pm 2 mmHg in Normal Pregnant (NP) to 123 \pm 3 mmHg in RUPP control rats. This response was attenuated by Abatacept, MAP was 104 \pm 2 mmHg in RUPP \pm A, and 96 \pm 2 mmHg NP \pm A. Percent circulating CD4⁺ T cells were 66 \pm 3% in RUPPs compared to 55 \pm 3% NP rats (p <0.04) but were normalized in RUPP \pm A rats (54 \pm 3%). The twofold increase in TNF alpha seen in RUPPs (277 \pm 47 pg/ml) was decreased to 80 \pm 18 pg/ml in RUPP+A. Placental sFlt-1 was reduced 70 % to 151 \pm 28 in RUPP \pm A compared 488 \pm 61 pg/ml in RUPP (p <0.001). AT1-AA decreased from 20 \pm 0.8 bpm in control RUPP to 6 \pm 0.7 bpm in RUPP \pm A. We next determined the effect of RUPP in causing hypertension in pregnant T cell deficient rats by examining MAP in NP (123 \pm 5 mmHg) and RUPP athymic nude rats (123 \pm 7 mmHg). In the absence of T cells, hypertension in response to placental ischemia was completely abolished. Collectively these data indicate that CD4⁺ T cells in response to placental ischemia play an important role in the pathophysiology of hypertension associated with preeclampsia.

Keywords: Hypertension; Preeclampsia; Placental ischemic insult

Introduction

Preeclampsia is a devastating disease of pregnancy affecting 5-7% of all pregnancies in the US [1,2]. While preeclampsia remains a significant contributor to maternal deaths, it is also a great cause of perinatal morbidity. For many patients, this disease is associated with devastating effects underscored by severe maternal morbidity. While the manifestations of preeclampsia do not appear until 20 weeks gestation, the disease process is hypothesized to begin at implantation [3-7]. During a normal pregnancy the invading trophoblasts remodel the uterine spiral arterioles creating a low resistance system allowing for increased blood volume delivery. When trophoblastic invasion is shallow, the arteriolar remodeling is blunted and the vascular resistance remains high, oxygenated blood flow is decreased and placental ischemia results. In addition to the fetal effects of impaired growth, placental ischemia has been shown to result in the production of vasoactive peptides and inflammatory cytokines [8-10]. These findings have been verified in the Reduced Uterine Perfusion Pressure (RUPP) model of preeclampsia, where pregnant rats that have surgically induced placental ischemia have elevated levels of circulating TNF- α , IL-6, IL-17, and sFlt-1 [8-13].

Newer research has begun to elucidate the role of the immune system in the pathogenesis of preeclampsia [14-21]. Many believe that partial failure of the maternal immune tolerance mechanisms precedes the development of placental oxidative stress and ischemia, both of which are major players in the pathophysiology of preeclampsia. This maternal immune tolerance involves crucial interactions between regulatory CD4⁺ T cells and uterine natural killer cells recognizing and accepting the fetal antigens and facilitating placental growth. Partial failure of this crucial step leads to poor placentation and dysfunctional placental perfusion and chronic immune activation originating in the placenta. Importantly, analysis of circulating blood collected from preeclamptic women has demonstrated a decrease in the proportion of circulating T regulatory cells [4,18]. Again, these findings are replicated in an animal model of preeclampsia which utilizes the RUPP procedure

which revealed that pregnant RUPP rats had a 47% decrease in FoxP3⁺ T regulatory cells in the peripheral circulation when compared to NP rats. This represents a shift from the normal anti-inflammatory Th2 state of pregnancy to the pro-inflammatory Th1 state [4,15,20].

While preeclampsia has not historically been classified as an autoimmune disorder, this shift in humoral immunity and production of autoantibodies certainly indicates that perhaps it should. In fact, T helper 17 cells, which have been known to upregulate in autoimmune disorders including lupus, psoriasis, and multiple sclerosis, are increased in preeclamptic women [4,15,18-20]. With a loss of T regulatory cells, the body loses the normal protection it has against the creation of autoantibodies. One of the most promising findings indicating the importance of T cells has been the discovery of a class 3 IgG molecule that stimulates the angiotensin type I receptor [17]. This agonistic autoantibody to the AT1receptor (AT1-AA) has been isolated from the sera of preeclamptic, but not normal pregnant women. These activating autoantibodies to the angiotensin type 1 receptor have been shown in an animal model to result in enhanced sensitivity to angiotensin [17]. Infusion of AT1-AA resulted in an exaggerated response to angiotensin II, a phenomenon which is known to occur in women with preeclampsia, the mechanism by which was previously unexplained. Further, chronic infusion of the AT1-AA has also been shown to increase production of sFlt-1 and soluble endoglin, activation of the ET-1 pathway and placental oxidative stress, all of

*Corresponding author: Babbette LaMarca, Basic Sciences, MFM Thesis Director, Dept of Obstetrics & Gynecology, University of Mississippi Medical Center, 2500 N State St, Jackson MS 39216, USA, E-mail: bblamarca@umc.edu

Received March 21, 2013; Accepted June 14, 2013; Published June 17, 2013

Citation: Novotny S, Wallace K, Herse F, Moseley J, Darby M, et al. (2013) CD4⁺ T Cells Play a Critical Role in Mediating Hypertension in Response to Placental Ischemia. J Hypertens 2: 116. doi:[10.4172/2167-1095.1000116](http://dx.doi.org/10.4172/2167-1095.1000116)

Copyright: © 2013 Novotny S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

which are important players in the pathophysiology of preeclampsia [10-13,16,17,21,22].

We have recently demonstrated that magnetically separated and cultured CD4⁺ T cells from RUPP rats secrete greater amounts of TNF alpha, IL-6, IL-17 and sFlt-1 into their cell culture media compared to NP CD4⁺ T cells [23]. Further, adoptive transfer of CD4⁺ T cells from RUPP dams into NP dams results in increased blood pressure and elevations in many factors shown to be stimulated by placental ischemia in the RUPP rat, such as sFlt-1, ET-1, TNF alpha, IL-6 and AT1-AA [11,23]. However a role for endogenous T cells to mediate secretion of such factors and hypertension in response to placental ischemia remained unidentified. Therefore the objective of the current study was to determine the effects of inhibiting endogenous T cell co-stimulation prior to placental injury on blood pressure and placental ischemia stimulated soluble factors. Two approaches were taken to answer this question. First, abatacept (Orencia) which is a fusion molecule of CTLA 4 designed to inhibit co-stimulation of T cells in response to antigens, was administered to pregnant rats on gestational day 13, RUPP was induced on day 14 and blood pressure and soluble factors were collected on day 19. Inhibition of T cell co-stimulation has proven efficient in other animal models of autoimmune disease and is now being used clinically to treat patients in various chronic inflammatory states such as hepatitis B and rheumatoid arthritis [5,6]. A second approach was to examine the hypertensive effect of RUPP on athymic nude T cell deficient pregnant rats.

Materials and Methods

All animal studies were performed in timed pregnant Sprague Dawley rats or Athymic Nude virgin or pregnant rats purchased from Harlan Inc (Indianapolis, IN). Animals were housed in a temperature controlled room (23°C) with a 12:12 light:dark cycle. Athymic nude rats were housed in an isolated barrier temperature controlled room (23°C) with a 12:12 light:dark cycle. All experimental procedures executed in this study were in accordance with the NIH guidelines for the use and care of animals. All protocols were approved by the Institutional Animal Care and Use Committee (IACUC) and the University of Mississippi Medical Center.

Inhibition of T cell co-stimulation in the Reduced Uterine Perfusion Pressure (RUPP) rat model of preeclampsia

To determine the role of endogenous T cells in mediating hypertension in RUPP rats, four groups of pregnant rats were examined: normal pregnant (NP, n=20), Reduced uterine perfusion pressure (RUPP, n=20), NP + Orencia (Abatacept) (NP+A; n=12) and RUPP + Orencia (Abatacept) (RUPP ± A; n=19). Orencia, Abatacept, (250mg/kg) was infused IV via jugular catheter over a 20 minute period on day 13 to NP (n=31) rats, 19 of which underwent the RUPP surgical procedure on day 14, same day as RUPP controls. The RUPP procedure reduces the uterine perfusion pressure with the application of a constrictive silver clip (0.203 mm) to the aorta superior to the iliac bifurcation performed via a midline laparotomy. Ovarian collateral circulation to the uterus is reduced with restrictive clips (0.100 mm) to the bilateral uterine arcades at the ovarian end. Under isoflourane anesthesia restrictive clips are implanted on day 14 of gestation. On day 18 of gestation carotid arterial catheters were inserted for blood pressure measurements. The catheters inserted are V3 tubing (SCI) which is tunneled to the back of the neck and exteriorized. On day 19 of gestation arterial blood pressure was analyzed after placing the rats in individual restraining cages. Arterial pressure was monitored with a pressure transducer (Cobe III Transducer CDX Sema) and recorded

continuously after a one hour stabilization period. Serum, plasma, and tissues were collected under isoflourane anesthesia on day 19 of gestation for molecular analysis. Plasma and serum were stored at -20°C and tissues at -80°C.

Determination of circulating T lymphocytes in response to Orencia (Abatacept) administration

Total populations of circulating CD4⁺ and CD8⁺ T cells were measured from peripheral blood leukocytes (PBL) collected at day 19 of gestation from pregnant RUPP rats with and without administration of Abatacept. We utilized flow cytometry analysis to detect percent circulating CD4⁺ and CD8⁺ T cell populations isolated from RUPP and NP rat PBLs. At the time of tissue harvest, plasma was collected and PBLs were isolated from plasma by centrifugation on a cushion of Ficoll-Hypaque (Lymphoprep, Accurate Chemical Corp) according to the manufacturer's directions. For flow cytometric analysis equal numbers of leukocytes (1×10^6) were incubated for 30 minutes at 4°C with antibodies against mouse CD₄ and mouse CD8 (BD Biosciences, San Jose, CA). After washing, cells were labeled with the secondary Fluorescein Isothiocyanate (FITC) Phycoerythrin (PE) antibodies (Southern Biotech, Birmingham, AL) for 30 minutes at 4°C. As a negative control, for each individual rat, cells were treated exactly as described above except they were incubated with anti-FITC and anti-PE secondary antibodies alone. Subsequently, cells were washed and suspended in 500 µl of Roswell Park Memorial Institute medium (RPMI) and analyzed for single staining on a Gallios flow cytometer (Beckman Coulter, Brea, CA). The percent of positive staining cells above the negative control was collected for each individual rat and mean values for each experimental group (RUPP and RUPP + A) was calculated.

Determination of AT1-AA production in response to blockade of CD4⁺ T cells prior to placental ischemic insult

Antibodies were detected by the chronotropic responses to AT1 receptor-mediated stimulation of cultured neonatal rat cardiomyocytes coupled with receptor-specific antagonists as previously described [10-13,16,17]. Briefly, on day 18 of gestation blood was collected and immunoglobulin was isolated from one ml of serum by specific anti-rat IgG column purification. Subsequently, AT1-AA was purified by the 7 amino acid epitope binding from the column purified rat IgG. AT1-AA activity was measured, as previously described, utilizing a bioassay that we have previously published in which the chronotropic response of rat neonatal cardiomyocytes in culture is detected and counted. Increased chronotropic response is counted and expressed as the change in beats/minute (Δ bpm) of the rat neonatal cardiomyocytes in culture, therefore units of AT1-AA are expressed as Δ bpm over basal levels.

TNF- α in response to inhibition of T cell co-stimulation prior to placental ischemic insult

A rat TNF- α colorimetric sandwich ELISA (R&D Systems) was used for quantification of serum TNF- α levels between 12.5 and 800 pg/ml. This assay displayed a sensitivity level of 5 pg/ml and interassay variability of 10% and intra-assay variability of 5.1%.

Placental sFlt-1 in response to inhibition of T cell co-stimulation prior to placental ischemic insult

We have shown that placental explants from RUPP rats or AT1-AA infused rats displayed increased placental production of sFlt-1. Further we demonstrated that RUPP CD4⁺ T cells secrete sFlt-1 *in vitro* and stimulate sFlt-1 elevation in NP recipient rats of RUPP

CD4⁺ T cells. Therefore, we hypothesized that production of sFlt-1 would be attenuated by suppressing T cells in RUPP rats treated with Abatacept prior to the placental ischemic insult (described above). Freshly harvested placentas collected from four control RUPPs and six RUPP+A rats were rinsed in cold phosphate buffered saline and the myometrium layer was isolated from the decidua and the vascular bundle was excised. Villous explants were plated on matrigel 6-well cell culture filter inserts and cultured in Dulbecco's modified Eagle medium/F12 supplemented with 0.25 µg/ml ascorbate and 10U Pen/Strep at 37°C, 6% O₂, 89% N₂, 5% CO₂ conditions [13]. Culture media was analyzed for sFlt-1 secretion via ELISA, Murine vascular endothelial growth factor R1 enzyme-linked immunosorbent assay from R&D Systems. The variability for intra-assay was 7.2% and interassay was 8.4%.

Uterine artery resistive index in response to inhibition of T cell co-stimulation prior to placental ischemic insult

In a method described by Tam Tam [24] Power Doppler velocimetry measurements were performed on anesthetized pregnant dams at an imaging station with a Vevo 770 unit (Visual sonics) using a 30 Hz transducer and an insonating angle <30°. The Peak Systolic flow Velocity (PSV) and End Diastolic flow Velocity (EDV) were recorded using the uterine artery Doppler waveform. The uterine artery resistive index was calculated using the following formula: UARI= (PSV-EDV)/PSV. Uterine artery resistive index was determined for the uterine artery bilaterally at three levels and the mean was calculated for control RUPPs and compared to RUPPs + A.

Statistical analysis

All data are expressed as mean ± standard error. Differences between control and experimental groups were analyzed using the Student's t-test for renal function. Blood pressure analysis and AT1-AA levels were analyzed using 1 way ANOVA for comparison among multiple groups. Values were of p<0.05 were considered significant.

Results

Effect of inhibition of T cell stimulation prior to placental ischemic insult on blood pressure, AT1-AA, TNF alpha, placental sFlt-1 and uterine artery resistive index

Percent circulating CD4⁺ T cells increased in RUPPs compared to NP rats, 66 ± 3% and 55.5±2.7% respectively (p<0.04). Administration of Abatacept attenuated the rise in circulating T cells in RUPP rats compared to RUPP controls. Circulating CD4⁺ T cells were normalized to 54.8 ± 2.5% in RUPP+A rats. Abatacept had no effect of circulating CD4⁺ T cells in NP rats, CD4⁺ T cells were 59 ± 4% in NP+A (Figure 1). CD8⁺ T cells are not significantly different from NP to RUPP control rats (24 ± 4% to 29 ± 5%). Administration of abatacept had no effect to decrease CD8⁺ T cells in either NP (25 ± 5%) or RUPP rats (25 ± 5%) illustrating the specificity and efficiency of abatacept on CD4⁺ T cells (Figure 1).

MAP increased from 94 ± 2 mmHg in NP rats to 123 ± 3 mmHg in RUPP rats. This hypertensive response was attenuated with inhibition of CD4⁺ T cell stimulation in RUPP rats. MAP was 96 ± 2 mmHg in NP+A, and only increased 8 mmHg to 104 ± 2 mmHg in RUPP+A (Figure 2). Pup weights were significantly decreased in RUPP rats compared to NP rats (1.97 ± 0.05 vs 2.24 ± 0.05 grams) and decreased further to 1.8 ± 0.04 grams in RUPP+A but were unchanged in NP + A (2.13 ± 0.04grams). No other morphological changes were noted in pups of RUPP rats treated with Abatacept.

Administration of Abatacept significantly decreased circulating CD4⁺ T cells in RUPP rats




Figure 1: Administration of Abatacept significantly decreased circulating CD4⁺ T cells in RUPP rats. As previously shown circulating CD4⁺ T cells are increased in RUPP rats compared to NP rats. There is no difference in circulating CD8⁺ T cells. This figure illustrates that with IV administration of orencia circulating T cells are normalized (P<0.0018) compared to RUPP rats.

Inhibition of T cell stimulation blunts the blood pressure response to placental ischemia during pregnancy




Figure 2: Inhibition CD4⁺ T cell co-stimulation blunts the blood pressure response to placental ischemia during pregnancy. As previously shown, blood pressure increases in RUPP rats, approximately 25 mmHg (P<0.01). Inhibition of T cell co-stimulation ultimately leads to suppressed blood pressure response to placental ischemia. RUPPs treated with Abatacept displayed an 8 mmHg increase in blood pressure compared to NP rats treated with Abatacept. This difference what not statically significant. However, RUPP+ Ado display significantly less blood pressure increase than control RUPPs (P<0.01). Pup weight is consistently decreased in RUPP rats compared to NP rats, however, pup weight was not improved with T cell blockade in RUPP rats.

Placental ischemia significantly increased AT1-AA production in RUPP compared to NP controls, as measured by an increase in cardiomyocyte chronotropic events expressed as beats per minute (bpm). NP rats display a 1.3 ± 0.6 bpm in cardiomyocyte chronotropic events while RUPP rats have significantly higher levels of 20 ± 0.41 bpm in cardiomyocyte chronotropic events. No change in cardiomyocyte chronotropic events were seen in NP rats treated with Abatacept (NP+A 0.67 ± 0.47 bpm). However, in stark contrast, inhibition of CD4⁺ T cell co-stimulation had a significant effect to decrease AT1-AA production in RUPP rats treated with Orenia, RUPP+A displayed 6.4 ± 0.755 bpm (Figure 3).

The two fold increase in circulating TNF alpha characteristically seen in RUPP rats (277 ± 47 pg/ml) was significantly decreased to 80 ± 18 pg/ml in RUPPs+A. Placental explant secretion of sFlt-1 at 2 hrs of culture was 186 ± 60 in RUPPs, but was decreased to 53 ± 7 pg/ml in RUPP rats treated with Abatacept. Placental explant secretion of sFlt-1 at 24 hrs culture was 488 ± 61 pg/ml in RUPP placentas but was significantly decreased to 151 ± 28 pg/ml in placentas from RUPP+A rats (p<0.001) (Figure 4). Uterine artery resistive index increased from 0.6 ± 0.02 in NP dams to 0.68 ± 0.02 in RUPP dams. Blockade of CD4⁺ T cells normalized uterine artery resistive index to 0.61 ± 0.03 in RUPP+A pregnant rats.

Effect of RUPP on athymic nude pregnant rats

Virgin and normal pregnant athymic nude rats were obtained from Harlan. Four underwent the RUPP procedure on day 14 of gestation and four were utilized as controls. Inducing placental ischemia in CD4⁺ T cell deficient pregnant rats had no effect to increase blood pressure during pregnancy. MAP in control athymic nude rats was 114 ± 5 mmHg. MAP in control athymic nude pregnant rats was 123 ± 5 mmHg. MAP in RUPP athymic nude rats was 123 ± 7 mmHg (Figure 5).

Discussion

While the immunologic profiles of preeclamptic women have been well described, the stimulus for the immunologic shift that occurs between a normal and preeclamptic pregnancy is not understood [3,7,15,18-20,23]. Previous work has demonstrated that both TNF-α and the AT1-AA can serve to stimulate the production of sFlt-1 from the placenta during pregnancy [12]. Our previous adoptive transfer data shows that CD4⁺ T cells stimulated in response to placental ischemia can induce a preeclamptic like state in a normal pregnant rat without any additional stimulus [11,23].

It was also demonstrated that adoptive transfer of placental ischemic stimulated CD4⁺ T cells were responsible for alterations in renal hemodynamics [11]. As previously described by Alexander et al. in 2001 [25], reduction in uterine perfusion pressure during pregnancy is associated with decreased glomerular filtration rate, increased renal vascular resistance, and decreased renal perfusion flow. This profile of altered renal hemodynamics was similar to the profile attained with




Figure 4: Inhibition of T cell co-stimulation attenuates production of TNF-α and placental sFlt-1 in RUPP pregnant rats. Placental ischemia stimulates TNF alpha and placental sFlt-1. Administration of Abatacept and suppression of T cells decreased circulating TNF alpha and placental secreted sFlt-1 in RUPP+ A compared to RUPP control rats.




Figure 5: T cells play a critical role in mediating hypertension in response to placental ischemia. Inducing placental ischemia in pregnant rats deficient in T cells had no effect to increase blood pressure during pregnancy. Both NP and RUPP in athymic/nude rats had blood pressures of 123 mmHg.

exposure to placental ischemic stimulated CD4⁺ T cells without any mechanical reduction in uterine perfusion [11]. This suggests that it is not the actual mechanical decrease in blood flow that leads to the altered renal hemodynamics, but rather, the immunologic response to that stimulus. It is likely that these findings also suggest that while immune activation plays a large role in the alteration of renal hemodynamics, it is just one of a myriad of stimuli working together *in vivo* to create the preeclamptic phenotype.

The hypertensive response to RUPP CD4⁺ T Lymphocytes was attenuated by AT1 receptor blockade with Losartan [11]. It is not clear whether the reduction in MAP was due to blockade of the AT1-AA or blockade of endogenous AngII activation of AT1 receptor. This question was answered with B cell depletion with Rituximab. Once the CD₂₀ costimulating molecule is blocked, endogenous B cells are




Figure 3: Inhibition of T cell co-stimulation attenuates production of AT1-AA in response to placental ischemia during pregnancy. We have consistently demonstrated AT1-AA produced in response to placental ischemia. With T cell suppression, AT1-AA is significantly lowered in RUPP+A compared to control RUPPs (P<0.05).

not stimulated to produce antibodies. By treating NP+RUPP CD4⁺T cell injected rats with Rituximab, AT1-AA levels were significantly suppress and MAP was decreased to NP levels [11].

Because B cell depletion with an anti-CD20 compound has been demonstrated to decrease production of the AT1-AA during pregnancy in response to surgical placental ischemia [13], and it was demonstrated in this data that MAP in response to adoptive transfer of ischemic stimulated CD4⁺ T cells was reduced with the same compound, these findings posed the question whether blockade of the interaction between the antigen presenting cell and the T cell could have the same results. CTLA-4, homologous to CD28, is expressed on activated T cells and binds to its ligand B7 as an important co-stimulatory signal to T cells [26]. Orenia (Abatacept) is a CTLA-4 immunoglobulin used experimentally to inhibit the T cell immune response by blocking this interaction. In this study, treatment of RUPP rats with Orenia (abatacept) prior to the placental insult was shown to significantly decrease MAP when compared to untreated RUPP rats. The reduction in MAP occurs in parallel with a significant reduction in AT1-AA from treated RUPP rats (Figure 2 and 3). This reduction in MAP, and suppression of AT1-AA production, was further explained by examining the absolute percentage of T cells in each group. The RUPP+A rats had circulating CD4⁺ T cell levels more similar to NP than RUPP rats (Figure 1). Further examination of the effect of CD4⁺ T cell blockade demonstrated that increased secretion of TNF- α and placental sFlt-1 in response to RUPP in pregnant rats were also significantly reduced. We have previously published that the RUPP rat model of PE has increased circulating TNF- α and placental secretion of the anti-angiogenic factor sFlt-1 (Figure 4) [6-13,23,24]. We have previously shown that RUPP CD4⁺ T cells are important sources of these factors. In this study we demonstrate the importance of T cells to be associated with increased secretion of these factors in response to placental ischemia by demonstrating that inhibition of CD4⁺ T cell stimulation prevents elevations in TNF alpha and placental sFlt-1 in association with hypertension in response to placental ischemia.

Additionally, we have shown that RUPP rats display a significant rise in uterine artery resistive index [24]. In 2011, Tam Tam, demonstrated similar findings in reductions in uterine artery resistive index in RUPP rats treated with an endothelin antagonist. The significant increase in uterine artery resistive seen in rats having undergone the RUPP procedure was also attenuated in the group of RUPP rats treated with Abatacept. These findings are similar to the renal hemodynamic findings, in that although it seems as though alterations in blood flow with RUPP are largely due to the mechanical obstruction caused by the RUPP procedure, there is an additional component stimulated by the response to placental ischemia that acts in concert to mediate the other pathophysiological components in RUPP rats that are seen in preeclamptic women. Interestingly, pup weights of RUPPs+A were less than the control RUPPs (Figure 2). However, no other fetal abnormalities were noted nor reductions in litter sizes were noted.

To further illustrate the importance of T cells in mediating hypertension in response to placental ischemia, we performed the RUPP procedure in athymic/nude pregnant rats, rats deficient in T cells. We demonstrate a lack of blood pressure response in RUPP athymic/nude pregnant rats, thereby confirming our hypothesis that T cells are important to cause hypertension in response to placental ischemia (Figure 5).

These findings lend hope that one day there will be an acceptable treatment for preeclampsia. While no current treatments are able to modify the failed trophoblastic invasion of the uterine spiral arterioles,

these findings in the RUPP model show that although surgically reduced uterine perfusion is present, the effects of preeclampsia with respect to T helper cells, MAP, AT1-AA production, and cytokine profiles can be pharmacologically improved to mimic normal pregnant levels and thus lead to a more normal pregnancy.

Perspectives and Significance

It has been demonstrated that CD4⁺ T cells in response to placental ischemia are responsible for hypertension, alterations in renal hemodynamics, production of inflammatory cytokines and anti-angiogenic molecules, as well as stimulating the production of agonistic autoantibodies to the angiotensin type I receptor. The effects of placental ischemia on blood pressure and many facets seen in preeclampsia can be attenuated with inhibition of T cells either by blockade of antigen presenting cells interacting with T cells or by overall T cell deficiency. Importantly, these data suggests the potential use of anti-inflammatory targeting T cell suppression as a therapeutic for preeclampsia. These studies highlight the importance of targeting CD4⁺ T cell suppression as an avenue to decrease blood pressure, cytokine production, anti-angiogenic factors, autoantibodies and uterine artery resistive index to improve preeclampsia symptoms late in pregnancy in PE women. Targeting the overactive immune system late in pregnancy in PE women could be a safe and potential therapeutic to improve pregnancy outcomes in women with this disease.

Sources of Funding

This work was supported by NIH grants HL78147 and HL51971 and HD067541. RD is supported by the German Research Foundation (DFG 631/7-1).

References

1. Sibai BM, Caritis S, Hauth J; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network (2003) What we have learned about preeclampsia. *Semin Perinatol* 27: 239-246.
2. Roberts JM, Lain KY (2002) Recent insights into the pathogenesis of preeclampsia. *Placenta* 9: 147-160.
3. de Melo BC, de Amorim MM, Katz L, Coutinho I, Verissimo G (2010) Uterine artery Doppler in the third trimester of pregnancy and postnatal outcome of patients with severe preeclampsia. *Hypertens Pregnancy* 29: 135-147.
4. Redman CW, Sargent IL (2010) Immunology of pre-eclampsia. *Am J Reprod Immunol* 63: 534-543.
5. von Kempis J, Dudler J, Hasler P, Kyburz D, Tyndall A, et al. (2012) Use of abatacept in rheumatoid arthritis. *Swiss Med Wkly* 142: w13581.
6. Kim PS, Ho GY, Prete PE, Furst DE (2012) Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. *Arthritis Care Res (Hoboken)* 64: 1265-1268.
7. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP (2001) Expression of inflammatory cytokines in placentas from women with preeclampsia. *J Clin Endocrinol Metab* 86: 2505-2512.
8. LaMarca BB, Bennett WA, Alexander BT, Cockrell K, Granger JP (2005) Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor- α . *Hypertension* 46: 1022-1025.
9. LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP (2007) Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. *Curr Hypertens Rep* 9: 480-485.
10. LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, et al. (2008) Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. *Hypertension* 52: 1168-1172.
11. Novotny SR, Wallace K, Heath J, Moseley J, Dhillon P, et al. (2012) Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4⁺ T lymphocytes from placental ischemic rats. *Am J Physiol Regul Integr Comp Physiol* 302: R1197-1201.

12. Parrish M, Murphy S, Rutland S, Wallace K, Wenzel K, et al. (2010) The effect of immune factors, tumor necrosis factor- α , and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. *Am J Hypertens* 23:911-916.
13. LaMarca B, Wallace K, Herse F, Wallukat G, Martin JN Jr, et al. (2011) Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes. *Hypertension* 57: 865-871.
14. Laresgoiti-Servitje E, Gómez-López N, Olson DM (2010) An immunological insight into the origins of pre-eclampsia. *Hum Reprod Update* 16: 510-524.
15. Sargent IL, Borzychowski AM, Redman CW (2006) Immunoregulation in normal pregnancy and preeclampsia: an overview. *Reprod Biomed Online* 12:680-686.
16. Wenzel K, Rajakumar A, Haase H, Geusens N, Hubner N, et al. (2011) Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. *Hypertension* 58: 77-84.
17. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, et al. (1999) Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. *J Clin Invest* 103: 945-952.
18. Prins JR, Boelens HM, Heimweg J, Van der Heide S, Dubois AE, et al. (2009) Preeclampsia is associated with lower percentages of regulatory T cells in maternal blood. *Hypertens Pregnancy* 28: 300-311.
19. Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, et al. (2009) Systemic increase in the ratio between Foxp3⁺ and IL-17-producing CD4⁺ T cells in healthy pregnancy but not in preeclampsia. *J Immunol* 183: 7023-7030.
20. Matthiesen L, Berg G, Ernerudh J, Ekerfelt C, Jonsson Y, et al. (2005) Immunology of preeclampsia. *ChemImmunol Allergy* 89: 49-61.
21. Xia Y, Kellems RE (2009) Is preeclampsia an autoimmune disease? *ClinImmunol* 133: 1-12.
22. Parrish MR, Wallace K, Tam Tam KB, Herse F, Weimer A, et al. (2011) Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension. *Am J Hypertens* 24: 835-840.
23. Wallace K, Richards S, Dhillon P, Weimer A, Edholm ES, et al. (2011) CD4⁺ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. *Hypertension* 57: 949-955.
24. Tam Tam KB, George E, Cockrell K, Arany M, Speed J, et al. (2011) Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. *Am J ObstetGynecol* 204: 330.
25. Alexander BT, Kassab SE, Miller MT, Abram SR, Reckelhoff JF, et al. (2001) Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. *Hypertension* 37: 1191-1195.
26. Abbas A (2011) *Cellular and Molecular Immunology*. Philadelphia. Elsevier.

Citation: Novotny S, Wallace K, Herse F, Moseley J, Darby M, et al. (2013) CD4⁺ T Cells Play a Critical Role in Mediating Hypertension in Response to Placental Ischemia. *J Hypertens* 2: 116. doi:[10.4172/2167-1095.1000116](https://doi.org/10.4172/2167-1095.1000116)

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 250 Open Access Journals
- 20,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscripts as E- mail: <http://www.omicsonline.org/submit/>

